Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-01-28Clinical Trial Update: Antineoplaston Therapy in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on antineoplaston therapy for multiple myeloma; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2021-01-25Clinical Trial Update: Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating two lenalidomide dose regimens with low-dose dexamethasone for relapsed multiple myeloma has completed a…
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Stem Cell Transplant for Hematological Malignancy [NA]
Clinical trial update on stem cell transplantation for hematologic malignancies; status terminated with results posted in 2021.
-
FDA approval · 2021-01-15FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) from Janssen Biotech, Inc., updating the pr…
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor [Phase 2, Phase 3]
Clinical trial update on ATIR donor lymphocyte preparation for haploidentical stem cell transplantation; study terminated with posted result…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation [Phase 2]
Phase 2 clinical trial update evaluating TKI258 in relapsed or refractory multiple myeloma, with or without t(4;14) translocation.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency [Phase 2]
Phase 2 clinical trial in untreated multiple myeloma patients with renal insufficiency has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-16Clinical Trial Update: Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients [Phase 2]
Phase 2 trial investigating ibrutinib in high risk smoldering multiple myeloma was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2020-12-07Clinical Trial Update: Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating bendamustine, bortezomib (Velcade), and dexamethasone in elderly patients with multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-04Clinical Trial Update: Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant [Phase 2]
Phase 2 trial update for Id-KLH vaccine combined with T cells in multiple myeloma patients undergoing transplant; results posted after compl…
-
FDA approval · 2020-12-03FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2020-12-02Clinical Trial Update: Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide [Phase 2]
A Phase 2 trial evaluating Plitidepsin (Aplidin) in combination with bortezomib and dexamethasone in multiple myeloma patients who are doubl…
-
FDA label_change · 2020-11-20FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for POMALYST (pomalidomide) by Celgene, resulting in changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2020-11-18Clinical Trial Update: Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) [Phase 1]
Phase 1 trial evaluating vorinostat (MK-0683) with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma has completed w…
-
CLINICAL_TRIALS trial_result · 2020-11-10Clinical Trial Update: A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) [Phase 3]
A Phase 3 trial evaluating oral ixazomib as maintenance therapy in newly diagnosed multiple myeloma patients who did not undergo stem cell t…
-
CLINICAL_TRIALS trial_result · 2020-11-06Clinical Trial Update: Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma [Phase 1]
Phase 1b trial assessing weekly carfilzomib with lenalidomide and dexamethasone in multiple myeloma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-11-04Clinical Trial Update: Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating lenalidomide, thalidomide, and dexamethasone in relapsed or refractory multiple myeloma has completed with result…
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 clinical trial update for APRIL CAR T cells (AUTO2) targeting BCMA and TACI in multiple myeloma; trial status terminated with post…
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: Aplidin - Dexamethasone in Relapsed/Refractory Myeloma [Phase 3]
Phase 3 trial update on Aplidin (plitidepsin) plus dexamethasone in relapsed/refractory multiple myeloma; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma [Phase 3]
Phase III trial evaluating lenalidomide and dexamethasone with or without elotuzumab in newly diagnosed, previously untreated multiple myelo…
-
FDA approval · 2020-10-20FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Zoledronic acid from Hikma Pharmaceuticals USA Inc., indicating regulatory approval for the spon…
-
CLINICAL_TRIALS trial_result · 2020-10-20Clinical Trial Update: Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma [Phase 2]
Phase 2 trial update evaluating carfilzomib, cyclophosphamide, and dexamethasone in transplant-eligible, high-risk newly diagnosed multiple …
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for ARRY-520 in relapsed or refractory multiple myeloma completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma [Phase 2]
Phase 2 trial evaluating bendamustine, prednisone, and Velcade for first-line treatment of symptomatic multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus [Phase 2]
Phase II trial of systemic Edmonston strain measles virus (oncolytic virotherapy) for multiple myeloma has completed with results posted.